Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuronASX:IMC Net Cash per Share is A$0.02 as of Dec. 2025, which is 100% below its 10-year median of 2.20. The stock has 4 warning signs investors should review. Among 793 Biotechnology companies, Immuron ranks better than 80.83% on this metric.
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Immuron Net Cash per Share Related Terms
Immuron Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Immuron's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMC vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Immuron's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Immuron's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Immuron's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a Net Cash per Share of A$0.02 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Immuron and its competitors. This is 99% below median its historical median of 2.20. Over the past decade, Immuron's Net Cash per Share has ranged from 0.88 to 27.00. According to the industry distribution chart, Immuron ranks #152 out of 793 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Immuron's Net Cash per Share too high?
Immuron's current Net Cash per Share of A$0.02 is 99% below median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 27.00. Based on the distribution chart, Immuron ranks #152 out of 793 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Immuron's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #152 out of 793 companies for Net Cash per Share. This places Immuron in the top 19% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.11. Historically, Immuron's own Net Cash per Share has ranged from 0.88 to 27.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.11, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Net Cash per Share is A$0.02, which is 99% below median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (ASX:IMC) has a current Net Cash per Share of A$0.02. The current Net Cash per Share is A$0.02, which is 99% below median its 10-year median of 2.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Net Cash per Share is A$0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 
